^
Association details:
Biomarker:CDYL2 overexpression
Cancer:HER2 Positive Breast Cancer
Drug Class:FAK inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Published date:
01/03/2022
Excerpt:
More importantly, HER2+ patients with high circCDYL2 had higher recurrence rate after trastuzumab treatment....Trastuzumab-resistance of HER2+ BC cells with high circCDYL2 could be reversed by FAK or GRB7 inhibitor....circCDYL2-GRB7-FAK complex plays a critical role in maintaining HER2 signaling, which contributes to trastuzumab resistance and circCDYL2 is a potential biomarker for trastuzumab-resistance in HER2+ BC patients.
DOI:
10.1186/s12943-021-01476-7